Cargando…

Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with psoriatic arthritis during the coronavirus disease (COVID‐19) pandemic: A case series

The COVID‐19 pandemic highlighted the benefits of subcutaneous (SC) administration for healthcare systems. The first SC infliximab, CT‐P13 SC, was safe and effective for the treatment of psoriatic arthritis. Observed patient preferences for continuing CT‐P13 SC suggest that patients receiving IV inf...

Descripción completa

Detalles Bibliográficos
Autores principales:	Baraliakos, Xenofon, Tsiami, Styliani, Vijayan, Sooraj, Jung, Haewon, Barkham, Nick
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2022
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8777045/ https://www.ncbi.nlm.nih.gov/pubmed/35079380 http://dx.doi.org/10.1002/ccr3.5205

Ejemplares similares

Real‐world evidence for subcutaneous infliximab (CT‐P13 SC) treatment in patients with ankylosing spondylitis during the coronavirus disease (COVID‐19) pandemic: A case series
por: Vijayan, Sooraj, et al.
Publicado: (2022)

High prevalence of chondrocalcinosis and frequent comorbidity with calcium pyrophosphate deposition disease in patients with seronegative rheumatoid arthritis
por: Krekeler, Martin, et al.
Publicado: (2022)

Pearls and Pitfalls in Diagnosing Non-Radiographic Axial Spondyloarthritis
por: Tsiami, Styliani, et al.
Publicado: (2022)

New developments in ankylosing spondylitis—status in 2021
por: Klavdianou, Kalliopi, et al.
Publicado: (2021)

Erratum to: New developments in Ankylosing spondylitis – Status in 2021
por: Klavdianou, Kalliopi, et al.
Publicado: (2022)

Dopamine receptor 1 expressing B cells exert a proinflammatory role in female patients with rheumatoid arthritis
por: Wieber, Karolin, et al.
Publicado: (2022)

Infliximab (Remicade) in the treatment of psoriatic arthritis
por: Mease, Philip
Publicado: (2006)

Serum granulocyte-macrophage colony-stimulating factor (GM-CSF) is increased in patients with active radiographic axial spondyloarthritis and persists despite anti-TNF treatment
por: Papagoras, Charalampos, et al.
Publicado: (2022)

Efficacy and safety of biosimilar infliximab CT-P13 in the treatment of psoriasis and psoriatic arthritis: 1-year follow-up
por: Kurizky, Patricia Shu, et al.
Publicado: (2019)

Peripheral spondyloarthritis and psoriatic arthritis sine psoriase: are we dealing with semantics or clinically meaningful differences?
por: Ziade, Nelly, et al.
Publicado: (2022)

Effectiveness and safety of a biosimilar-to-biosimilar switch of the TNF inhibitor etanercept in patients with chronic inflammatory rheumatic diseases
por: Kiltz, Uta, et al.
Publicado: (2022)

Budget impact analysis of the subcutaneous infliximab (CT-P13 SC) for treating inflammatory bowel disease in the Big-5 European (E5) countries
por: Yoo, Hyun Kyeong, et al.
Publicado: (2022)

Population pharmacokinetics of subcutaneous infliximab CT‐P13 in Crohn’s disease and ulcerative colitis
por: Hanzel, Jurij, et al.
Publicado: (2021)

Infliximab Induces Increase in Triglyceride Levels in Psoriatic Arthritis Patients
por: Castro, Karla R., et al.
Publicado: (2011)

Psoriatic Arthritis That Responded Dramatically When Infliximab Was Switched to Adalimumab
por: Ohshima, Yuichiro, et al.
Publicado: (2013)

Development of Eosinophilic Fasciitis during Infliximab Therapy for Psoriatic Arthritis
por: Hariman, Richard, et al.
Publicado: (2016)

Infliximab-Induced Aseptic Meningitis during the Treatment of Psoriatic Arthritis
por: Matsuura-Otsuki, Yuki, et al.
Publicado: (2017)

Are patients with rheumatic diseases on immunosuppressive therapies protected against preventable infections? A cross-sectional cohort study
por: Kiltz, Uta, et al.
Publicado: (2021)

Treatment with adalimumab in patients with chronic inflammatory rheumatic diseases: a study of treatment trajectories on a patient level in routine care
por: Redeker, Imke, et al.
Publicado: (2023)

A Case of Phlegmonous Gastritis in a Patient with Psoriatic Arthritis on Infliximab
por: De Davide, Laurence, et al.
Publicado: (2018)

Imaging in rheumatoid arthritis, psoriatic arthritis, axial spondyloarthritis, and osteoarthritis: An international viewpoint on the current knowledge and future research priorities
por: Baraliakos, Xenofon, et al.
Publicado: (2019)

Efficacy and safety of CT-P13 (biosimilar infliximab) in patients with rheumatoid arthritis: comparison between switching from reference infliximab to CT-P13 and continuing CT-P13 in the PLANETRA extension study
por: Yoo, Dae Hyun, et al.
Publicado: (2017)

Symptomless Pulmonary Cryptococcosis in a Psoriatic Arthritis Patient during Infliximab Therapy
por: Yamada, Saori, et al.
Publicado: (2016)

Modulation of Dopamine Receptors on Osteoblasts as a Possible Therapeutic Strategy for Inducing Bone Formation in Arthritis
por: Schwendich, Elena, et al.
Publicado: (2022)

Achilles tendon enthesitis evaluated by MRI assessments in patients with axial spondyloarthritis and psoriatic arthritis: a report of the methodology of the ACHILLES trial
por: Baraliakos, Xenofon, et al.
Publicado: (2020)

Effectiveness and safety of infliximab for 11 years in a patient with erythrodermic psoriasis and psoriatic arthritis
por: Trídico, Lívia Arroyo, et al.
Publicado: (2017)

Efficacy and Safety of Elective Switching from Intravenous to Subcutaneous Infliximab [CT-P13]: A Multicentre Cohort Study
por: Smith, Philip J, et al.
Publicado: (2022)

Subcutaneous Infliximab [CT-P13], a True Biologic 2.0. Real Clinical Practice Multicentre Study
por: Huguet, Jose M., et al.
Publicado: (2022)

Assessing physician and patient acceptance of infliximab biosimilars in rheumatoid arthritis, ankylosing spondyloarthritis and psoriatic arthritis across Germany
por: Waller, John, et al.
Publicado: (2017)

Valuing Treatment With Infliximab for Ankylosing Spondylitis Using a Willingness‐to‐Pay Approach
por: Webers, Casper, et al.
Publicado: (2018)

Predictors of response to secukinumab in patients with psoriatic arthritis and axial manifestations: a post-hoc analysis of the MAXIMISE trial
por: Baraliakos, Xenofon, et al.
Publicado: (2022)

Impact on direct and indirect costs of switching patients with inflammatory bowel disease from intravenous to subcutaneous infliximab (CT-P13)
por: Carbery, Isabel, et al.
Publicado: (2023)

Characterisation of prodromal and very early psoriatic arthritis: a systematic literature review informing a EULAR taskforce
por: De Marco, Gabriele, et al.
Publicado: (2023)

Divergent Gene Activation in Peripheral Blood and Tissues of Patients with Rheumatoid Arthritis, Psoriatic Arthritis and Psoriasis following Infliximab Therapy
por: Rosenberg, Alexander, et al.
Publicado: (2014)

Clinical response to discontinuation of anti-TNF therapy in patients with ankylosing spondylitis after 3 years of continuous treatment with infliximab
por: Baraliakos, Xenofon, et al.
Publicado: (2005)

A population-based projection of psoriatic arthritis in Germany until 2050: analysis of national statutory health insurance data of 65 million German population
por: Wang, Jiancong, et al.
Publicado: (2023)

Comparative efficacy of subcutaneous (CT-P13) and intravenous infliximab in adult patients with rheumatoid arthritis: a network meta-regression of individual patient data from two randomised trials
por: Combe, Bernard, et al.
Publicado: (2021)

Secukinumab in patients with psoriatic arthritis and axial manifestations: results from the double-blind, randomised, phase 3 MAXIMISE trial
por: Baraliakos, Xenofon, et al.
Publicado: (2021)

Genetic and Molecular Distinctions Between Axial Psoriatic Arthritis and Radiographic Axial Spondyloarthritis: Post Hoc Analyses from Four Phase 3 Clinical Trials
por: Kavanaugh, Arthur, et al.
Publicado: (2023)

Infliximab plus methotrexate is superior to methotrexate alone in the treatment of psoriatic arthritis in methotrexate-naive patients: the RESPOND study
por: Baranauskaite, Asta, et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_tcgnsk8bbds9e8silfek16259j